Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies

Sheena K Aurora, Mitchell F Brin, Sheena K Aurora, Mitchell F Brin

Abstract

Several lines of research support the hypothesis that migraine is a spectrum of illness, with clinical symptoms that vary along a continuum from episodic migraine to chronic migraine. Physiologic changes may result in episodic migraine evolving into chronic migraine over months to years in susceptible individuals. With chronification, headache frequency increases, becoming more disabling and less responsive to therapy. Neurophysiologic and functional imaging research has reported that chronic migraine may be associated with severity-specific metabolic, functional, and structural abnormalities in the brainstem. Without longitudinal studies, it is unclear whether these changes may represent a continuum of individual progression and/or are reversible. Furthermore, chronic migraine is associated with larger impairments in cortical processing of sensory stimuli when compared with episodic migraine, possibly caused by more pronounced cortical hyperexcitability. Progressive changes in nociceptive thresholds and subsequent central sensitization due to recurrent migraine attacks in vulnerable individuals contribute to the chronic migraine state. This may result in changes to baseline neurologic function between headache attacks, evident in both electrophysiological and functional imaging research. Patients experiencing migraine chronification may report increased non-headache pain, fatigue, psychiatric disorders (eg, depression, anxiety), gastrointestinal complaints, and other somatic conditions associated with their long-term experience with migraine pain. Recent research provides a foundation for differentiating episodic and chronic migraine based on neurophysiologic and neuroimaging tools. In this literature review, we consider these findings in the context of models designed to explain the physiology and progression of episodic migraine into chronic migraine, and consider treatment of chronic migraine in susceptible individuals. Advances in pharmacotherapy provide treatment options for chronic migraine. Of the currently available treatment options, only onabotulinumtoxinA and topiramate have received regulatory approval and have demonstrated efficacy in patients with chronic migraine, although the exact mechanisms of action are not fully elucidated.

Keywords: chronic migraine; episodic migraine; literature review; onabotulinumtoxinA; pathophysiology; topiramate.

© 2016 The Authors Headache published by Wiley Periodicals, Inc. on behalf of American Headache Society.

Figures

Figure 1
Figure 1
Overview of features associated with episodic and chronic migraine.8 Of note, the ICHD‐3b criteria cited here do not differ substantially from the ICHD‐2 criteria, which many of the studies cited herein used to define migraine and chronic migraine.9, 10, 11, 12, 13 Source: Adapted and updated from Aurora.14
Figure 2
Figure 2
Cortical excitability as measured by magnetic suppression of perceptual accuracy. *P < .001. Stimulus onset accuracy is the time between the appearance of the letter trigram and the delivery of the TMS pulse. Bars show standard errors. Source: Aurora et al.12

References

    1. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the Migraine Disability Assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2003;43:336‐342.
    1. Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52:1456‐1470.
    1. Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35:563–578.
    1. Aurora SK, Kulthia A, Barrodale PM. Mechanism of chronic migraine. Curr Pain Headache Rep. 2011;15:57‐63.
    1. Wrobel Goldberg S, Silberstein SD. Targeting CGRP: A new era for migraine treatment. CNS Drugs. 2015;29:443‐452.
    1. Mitsikostas DD, Rapoport AM. New players in the preventive treatment of migraine. BMC Med. 2015;13:279.
    1. Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: Analysis of factors. Headache. 1982;22:66‐68.
    1. Headache Classification Committee of the International Headache Society . The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia . 2013;33:629‐808.
    1. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? Headache. 2001;41:629‐637.
    1. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1:658‐660.
    1. Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005;128:932‐939.
    1. Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache. 2007;47:996‐1003. discussion 1004‐1007.
    1. Kitaj MB, Klink M. Pain thresholds in daily transformed migraine versus episodic migraine headache patients. Headache. 2005;45:992‐998.
    1. Aurora SK. Is chronic migraine one end of a spectrum of migraine or a separate entity? Cephalalgia. 2009;29:597‐605.
    1. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742‐746.
    1. Olesen J, Steiner TJ. The International classification of headache disorders, 2nd edn (ICDH‐II). J Neurol Neurosurg Psychiatry. 2004;75:808‐811.
    1. Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med. 2006;354:158‐165.
    1. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010;30:599‐609.
    1. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48:7‐15.
    1. Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache. 2008;48:16‐25.
    1. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Chronic migraine is an earlier stage of transformed migraine in adults. Neurology. 2005;65:1556‐1561.
    1. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population‐based study. Pain. 2003;106:81‐89.
    1. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache. Headache. 2007;47:13‐21.
    1. Lipton RB, Penzien DB, Turner DP, Smitherman TA, Houle TT. Methodological issues in studying rates and predictors of migraine progression and remission. Headache. 2013;53:930‐934.
    1. Louter M, Fernandez‐Morales J, de Vries B, et al. Candidate‐gene association study searching for genetic factors involved in migraine chronification. Cephalalgia. 2015;35:500–507.
    1. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type‐2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87:543‐552.
    1. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003;33:192‐196.
    1. Pietrobon D. Migraine: New molecular mechanisms. Neuroscientist. 2005;11:373‐386.
    1. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365‐391.
    1. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994;117(Pt 1):199‐210.
    1. Noseda R, Burstein R. Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154(Suppl.1):S44‐53.
    1. Cady RK, Schreiber CP, Farmer KU. Understanding the patient with migraine: The evolution from episodic headache to chronic neurologic disease. A proposed classification of patients with headache. Headache. 2004;44:426‐435.
    1. Mongini F, Keller R, Deregibus A, Barbalonga E, Mongini T. Frontal lobe dysfunction in patients with chronic migraine: A clinical‐neuropsychological study. Psychiatry Res. 2005;133:101‐106.
    1. de Tommaso M, Losito L, Difruscolo O, Libro G, Guido M, Livrea P. Changes in cortical processing of pain in chronic migraine. Headache. 2005;45:1208‐1218.
    1. Obermann M, Gizewski ER, Limmroth V, Diener HC, Katsarava Z. Symptomatic migraine and pontine vascular malformation: Evidence for a key role of the brainstem in the pathophysiology of chronic migraine. Cephalalgia. 2006;26:763‐766.
    1. Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R. Cortical projections of functionally identified thalamic trigeminovascular neurons: Implications for migraine headache and its associated symptoms. J Neurosci. 2011;31:14204‐14217.
    1. Cooke L, Eliasziw M, Becker WJ. Cutaneous allodynia in transformed migraine patients. Headache. 2007;47:531‐539.
    1. Burstein R, Yarnitsky D, Goor‐Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614‐624.
    1. Bigal ME, Ashina S, Burstein R, et al. Prevalence and characteristics of allodynia in headache sufferers: A population study. Neurology. 2008;70:1525‐1533.
    1. Lovati C, D'Amico D, Rosa S, et al. Allodynia in different forms of migraine. Neurol Sci. 2007;28(Suppl.2):S220‐221.
    1. Zappaterra M, Guerzoni S, Cainazzo MM, Ferrari A, Pini LA. Basal cutaneous pain threshold in headache patients. J Headache Pain. 2011;12:303‐310.
    1. de Tommaso M, Valeriani M, Guido M, et al. Abnormal brain processing of cutaneous pain in patients with chronic migraine. Pain. 2003;101:25‐32.
    1. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559‐566.
    1. Penzien DB, Rains JC, Lipton RB. Introduction to the special series on the chronification of headache: Mechanism, risk factors, and behavioral strategies aimed at primary and secondary prevention of chronic headache. Headache. 2008;48:5‐6.
    1. Ferrari A, Leone S, Vergoni AV, et al. Similarities and differences between chronic migraine and episodic migraine. Headache. 2007;47:65‐72.
    1. Lipton RB. Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology. 2009;72:S3‐7.
    1. Silberstein SD, Dodick D, Freitag F, et al. Pharmacological approaches to managing migraine and associated comorbidities–clinical considerations for monotherapy versus polytherapy. Headache. 2007;47:585‐599.
    1. Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35:536–578.
    1. Freitag FG, Kozma CM, Slaton T, Osterhaus JT, Barron R. Characterization and prediction of emergency department use in chronic daily headache patients. Headache. 2005;45:891‐898.
    1. Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2009;49:498‐508.
    1. Goadsby PJ. Advances in the understanding of headache. Br Med Bull. 2005;73‐74:83‐92.
    1. Kim JH, Suh SI, Seol HY, et al. Regional grey matter changes in patients with migraine: A voxel‐based morphometry study. Cephalalgia. 2008;28:598‐604.
    1. Kruit M, van BM, Launer L, Terwindt G, Ferrari M. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: The population‐based MRI CAMERA study. Cephalalgia. 2010;30:129‐136.
    1. Kurth T, Mohamed S, Maillard P, et al. Headache, migraine, and structural brain lesions and function: Population based Epidemiology of Vascular Ageing‐MRI study. BMJ. 2011;342:c7357‐
    1. Granziera C, DaSilva AF, Snyder J, Tuch DS, Hadjikhani N. Anatomical alterations of the visual motion processing network in migraine with and without aura. PLoS Med. 2006;3:e402.
    1. Matharu MS, T Bartsch, N Ward, RS Frackowiak, R Weiner, PJ Goadsby. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain. 2004;127:220‐30.
    1. Chen WT, Wang SJ, Fuh JL, Lin CP, Ko YC, Lin YY. Persistent ictal‐like visual cortical excitability in chronic migraine. Pain. 2011;152:254‐258.
    1. Aurora SK, Barrodale P, Chronicle EP, Mulleners WM. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache. 2005;45:546‐552.
    1. Moliadze V, Zhao Y, Eysel U, Funke K. Effect of transcranial magnetic stimulation on single‐unit activity in the cat primary visual cortex. J Physiol. 2003;553:665‐679.
    1. Mulleners WM, Chronicle EP, Palmer JE, Koehler PJ, Vredeveld JW. Suppression of perception in migraine: Evidence for reduced inhibition in the visual cortex. Neurology. 2001;56:178‐183.
    1. Aurora SK. Spectrum of illness: Understanding biological patterns and relationships in chronic migraine. Neurology. 2009;72:S8‐13.
    1. Srikiatkhachorn A. Towards the better understanding about pathogenesis of chronic daily headache. J Med Assoc Thai. 2006;89(Suppl. 3):S234‐243.
    1. Welch KM, Cao Y, Aurora S, Wiggins G, Vikingstad EM. MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology. 1998;51:1465‐1469.
    1. Cao Y, Aurora SK, Nagesh V, Patel SC, Welch KM. Functional MRI‐BOLD of brainstem structures during visually triggered migraine. Neurology. 2002;59:72‐78.
    1. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995;60:3‐38.
    1. Brown LL, Schneider JS, Lidsky TI. Sensory and cognitive functions of the basal ganglia. Curr Opin Neurobiol. 1997;7:157‐163.
    1. Iadarola MJ, Berman KF, Zeffiro TA, et al. Neural activation during acute capsaicin‐evoked pain and allodynia assessed with PET. Brain. 1998;121 (Pt 5):931‐947.
    1. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001;98:4687‐4692.
    1. Bowyer SM, Aurora KS, Moran JE, Tepley N, Welch KM. Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol. 2001;50:582‐587.
    1. Tepper SJ, Lowe MJ, Beall E, et al. Iron deposition in pain‐regulatory nuclei in episodic migraine and chronic daily headache by MRI. Headache. 2012;52:236‐243.
    1. Kruit MC, Launer LJ, Overbosch J, van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: A population‐based magnetic resonance imaging study. Cephalalgia. 2009;29:351‐359.
    1. Mainero C, Boshyan J, Hadjikhani N. Altered functional magnetic resonance imaging resting‐state connectivity in periaqueductal gray networks in migraine. Ann Neurol. 2011;70:838‐845.
    1. Valfre W, Rainero I, Bergui M, Pinessi L. Voxel‐based morphometry reveals gray matter abnormalities in migraine. Headache. 2008;48:109‐117.
    1. Kruit MC, Thijs RD, Ferrari MD, Launer LJ, van Buchem MA, van Dijk JG. Syncope and orthostatic intolerance increase risk of brain lesions in migraineurs and controls. Neurology. 2013;80:1958‐1965.
    1. Maizels M, Aurora S, Heinricher M. Beyond Neurovascular: Migraine as a dysfunctional neurolimbic pain network. Headache. 2012;52:1553–1565.
    1. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia. 2014;34:853‐869.
    1. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord. 2011;17:S28‐33.
    1. Dodick D, Silberstein S. Central sensitization theory of migraine: Clinical implications. Headache. 2006;46(Suppl. 4):S182‐191.
    1. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998;79:964‐982.
    1. Malick A, Burstein R. Cells of origin of the trigeminohypothalamic tract in the rat. J Comp Neurol. 1998;400:125‐144.
    1. Malick A, Strassman RM, Burstein R. Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J Neurophysiol. 2000;84:2078‐2112.
    1. BOTOX (onabotulinumtoxinA for injection, for intramuscular, intradetrusor, or intradermal use). Irvine, CA: Full Prescribing Information, Allergan, Inc; 2013.
    1. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double‐blind, randomized, placebo‐controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793‐803.
    1. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56‐week PREEMPT clinical program. Headache. 2011;51:1358‐1373.
    1. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double‐blind, randomized, placebo‐controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804‐814.
    1. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double‐blind, randomized, placebo‐controlled phases of the PREEMPT clinical program. Headache. 2010;50:921‐936.
    1. Topamax (topiramate) tablets or sprinkle capsules for oral use Full Prescribing Information, Titusville, NJ: Janssen Pharmaceuticals, Inc; 2012.
    1. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: A randomized, double‐blind, placebo‐controlled study. Cephalalgia. 2007;27:814‐823.
    1. Mathew NT, Jaffri SF. A double‐blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: A pilot study. Headache. 2009;49:1466‐1478.
    1. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi‐center double‐blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51:21‐32.
    1. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43:S9‐15.
    1. Whitcup SM, Turkel CC, DeGryse RE, Brin MF. Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci. 2014;1329:67‐80.
    1. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155‐188.
    1. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP‐25. Nature. 1993;365:160‐163.
    1. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13(Suppl.4):1‐9.
    1. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785‐793.
    1. Hargreaves R. New migraine and pain research. Headache. 2007;47:S26‐S43.
    1. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245‐258.
    1. Durham PL, Cady R. Regulation of calcitonin gene‐related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache. 2004;44:35‐42. discussion 42‐33.
    1. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004;172:1529‐1532.
    1. Meng J, Ovsepian SV, Wang J, et al. Activation of TRPV1 mediates calcitonin gene‐related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti‐nociceptive potential. J Neurosci. 2009;29:4981‐4992.
    1. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin‐induced pain. Pain. 2004;107:125‐133.
    1. Gazerani P, Au S, Dong X, Kumar U, Arendt‐Nielsen L, Cairns BE. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain. 2010;151:606‐616.
    1. Zhang X, Strassman AM, Novack V, Brin MF, Burstein R. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulatin of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle? Cephalalgia. 2016;36:875‐886.
    1. Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174:977‐982. discussion 982‐973.
    1. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene‐related peptide, for the prevention of migraine: A phase 2, randomised, double‐blind, placebo‐controlled study. Lancet Neurol. 2014;13:885‐892.
    1. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene‐related peptide, for the prevention of frequent episodic migraine: A randomised, double‐blind, placebo‐controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100‐1107.
    1. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV‐48125 for preventive treatment of chronic migraine: A multicentre, randomised, double‐blind, placebo‐controlled, phase 2b study. Lancet Neurol. 2015;14:1091‐1100.
    1. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK‐0974 (telcagepant), a new oral antagonist of calcitonin gene‐related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo‐controlled, parallel‐treatment trial. Lancet. 2008;372:2115‐2123.
    1. Cernuda‐Morollon E, Ramon C, Martinez‐Camblor P, Serrano‐Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156:820‐824.
    1. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl. 1):S3‐9.
    1. Silberstein SD. Topiramate in migraine prevention. Headache. 2005;45(Suppl. 1):S57‐65.
    1. Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia. 2002;22:491‐512.
    1. Aurora SK, Barrodale PM, Vermaas AR, Rudra CB. Topiramate modulates excitability of the occipital cortex when measured by transcranial magnetic stimulation. Cephalalgia. 2010;30:648‐654.
    1. Artemenko AR, Kurenkov AL, Filatova EG, Nikitin SS, Kaube H, Katsarava Z. Effects of topiramate on migraine frequency and cortical excitability in patients with frequent migraine. Cephalalgia. 2008;28:203‐208.
    1. Ruiz L, Ferrandi D. Topiramate in migraine progression. J Headache Pain. 2009;10:419‐422.
    1. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt‐Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin‐induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141:60‐69.
    1. Gazerani P, Staahl C, Drewes AM, Arendt‐Nielsen L. The effects of botulinum toxin type A on capsaicin‐evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006;122:315‐325.
    1. Puretic MB, Demarin V. Neuroplasticity mechanisms in the pathophysiology of chronic pain. Acta Clin Croat. 2012;51:425‐429.
    1. Lipton RB, Bigal ME. Looking to the future: Research designs for study of headache disease progression. Headache. 2008;48:58‐66.
    1. Serrano D, Buse DC, Kori SH, et al. Effects of switching acute treatment on disability in migraine patients using triptans. Headache. 2013;53:1415‐1429.
    1. Calhoun AH, Ford S. Behavioral sleep modification may revert transformed migraine to episodic migraine. Headache. 2007;47:1178‐1183.
    1. Calhoun A, Ford S. Elimination of menstrual‐related migraine beneficially impacts chronification and medication overuse. Headache. 2008;48:1186‐1193.
    1. Rains JC. Chronic headache and potentially modifiable risk factors: Screening and behavioral management of sleep disorders. Headache. 2008;48:32‐39.
    1. Mathew NT. Pathophysiology of chronic migraine and mode of action of preventive medications. Headache. 2011;51(Suppl. 2):84‐92.
    1. Negro A, Curto M, Lionetto L, Martelletti P. A two years open‐label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: A real‐world experience. J Headache Pain. 2015;17:1.
    1. Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real‐life data in 254 patients from Hull, U.K. J Headache Pain. 2014;15:54.
    1. Rothrock JF, Bloudek LM, Houle TT, Andress‐Rothrock D, Varon SF. Real‐world economic impact of onabotulinumtoxinA in patients with chronic migraine. Headache. 2014;54:1565‐1573.
    1. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence‐based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707‐1714.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren